Julie Flygare: Rare Disease Patient Advocates and Orphan Drugs

For orphan drugs, the marketing strategy should include increasing awareness and education about the disease. This is a key mission for many rare disease advocacy groups. So in the orphan drug space, the best marketing has advocacy as a part of it. Siren invited a few rare disease patient leaders to attend the Rare Disease and Orphan Drug Leadership Congress in Philadelphia last week. We facilitated conversations around the topic of how biopharmaceutical companies can and should engage with patients.

Julie Flygare discusses living with narcolepsy with cataplexy, how she became an advocate and how she’s helped provide education to pharmaceutical company employees.

We welcome a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s